CA2151386A1 - Prevention and treatment of sepsis - Google Patents

Prevention and treatment of sepsis

Info

Publication number
CA2151386A1
CA2151386A1 CA002151386A CA2151386A CA2151386A1 CA 2151386 A1 CA2151386 A1 CA 2151386A1 CA 002151386 A CA002151386 A CA 002151386A CA 2151386 A CA2151386 A CA 2151386A CA 2151386 A1 CA2151386 A1 CA 2151386A1
Authority
CA
Canada
Prior art keywords
conjugate
igg
antibiotic
pmb
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002151386A
Other languages
English (en)
French (fr)
Inventor
Sean B. Carroll
Joseph R. Firca
Charles S. G. Pugh
Nisha Vikas Padhye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ophidian Pharmaceuticals Inc
Original Assignee
Sean B. Carroll
Joseph R. Firca
Charles S. G. Pugh
Nisha Vikas Padhye
Ophidian Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/169,701 external-priority patent/US5545721A/en
Application filed by Sean B. Carroll, Joseph R. Firca, Charles S. G. Pugh, Nisha Vikas Padhye, Ophidian Pharmaceuticals, Inc. filed Critical Sean B. Carroll
Publication of CA2151386A1 publication Critical patent/CA2151386A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C07K7/58—Bacitracins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
CA002151386A 1992-12-21 1993-12-20 Prevention and treatment of sepsis Abandoned CA2151386A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US99538892A 1992-12-21 1992-12-21
US16406793A 1993-12-08 1993-12-08
US08/169,701 1993-12-17
US08/164,067 1993-12-17
US07/995,388 1993-12-17
US08/169,701 US5545721A (en) 1992-12-21 1993-12-17 Conjugates for the prevention and treatment of sepsis

Publications (1)

Publication Number Publication Date
CA2151386A1 true CA2151386A1 (en) 1994-07-07

Family

ID=27388964

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151386A Abandoned CA2151386A1 (en) 1992-12-21 1993-12-20 Prevention and treatment of sepsis

Country Status (5)

Country Link
EP (1) EP0679083A4 (de)
JP (1) JPH08504824A (de)
AU (1) AU693433B2 (de)
CA (1) CA2151386A1 (de)
WO (1) WO1994014437A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO2007038623A2 (en) * 2005-09-28 2007-04-05 Ventria Bioscience Oral formulation for enteric disorders and/or rehydration
WO2023080797A1 (en) * 2021-11-05 2023-05-11 Koru Diagnostics Limited Method for detecting pathogenic gram-negative microorganisms and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067776A (en) * 1975-11-25 1978-01-10 Research Foundation Of Children's Hospital Method for differential diagnosis of meningitis with a limulus lysate test
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
WO1989004672A1 (en) * 1987-11-20 1989-06-01 The Upjohn Company Derivatives of lincosaminide antibiotics
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
AU639952B2 (en) * 1989-11-15 1993-08-12 Novartis Ag Polymyxin conjugates
AU2006892A (en) * 1991-05-16 1992-12-30 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
EP0664814A1 (de) * 1993-08-18 1995-08-02 MorphoSys AG Lipopolysaccharidbindende und neutralisierende peptide

Also Published As

Publication number Publication date
AU6226994A (en) 1994-07-19
WO1994014437A1 (en) 1994-07-07
EP0679083A1 (de) 1995-11-02
AU693433B2 (en) 1998-07-02
EP0679083A4 (de) 1999-03-24
JPH08504824A (ja) 1996-05-28

Similar Documents

Publication Publication Date Title
US5545721A (en) Conjugates for the prevention and treatment of sepsis
US6579696B1 (en) Polymyxin B conjugates
US6660267B1 (en) Prevention and treatment of sepsis
Gough et al. Antiendotoxin activity of cationic peptide antimicrobial agents
US7795402B2 (en) Anti-Staphylococcus aureus antibodies
JP4656728B2 (ja) ブドウ球菌抗原及びワクチン
JPH07501545A (ja) 非連鎖球菌系細菌感染症の治療方法
US10870710B2 (en) Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof
US5955074A (en) Directed human immune globulin for the prevention and treatment of staphylococcal infections
KR20090019007A (ko) 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
Poynton et al. Use of IgM enriched intravenous mmmMMlLLL (Pentaglobin) in bone marrow transplantation
AU693433B2 (en) Prevention and treatment of sepsis
US5998381A (en) Compounds that bind bacterial pili
WO1993017044A1 (en) Directed human immune globulin for the prevention and treatment of staphylococcal infections
KR20110124060A (ko) Ｗｔａ를 유효성분으로 함유하는 백신 조성물
AU6553899A (en) Prevention and treatment of sepsis
Trautmann et al. Endotoxin release due to ciprofloxacin measured by three different methods
Morhart et al. Evaluation of enzyme immunoassay for Candida cytoplasmic antigens in neutropenic cancer patients
JPH05505592A (ja) セプシスの治療用製剤製品
Torney et al. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus
Traub Interactions of Antimicrobial Drugs and Combined Phagocytic/Serum Bactericidal Activity of Defibrinated Human Blood against Serratia marcescens: I. Cotrimoxazole, Nalidixic Acid, Nitrofurantoin, and Trimethoprim
EP4212168A1 (de) Neuartige zusammensetzung zur prävention oder behandlung von infektionskrankheiten mit staphylococcus aureus
Aldridge et al. Antibody to endotoxin core glycolipid reverses reticuloendothelial system depression in an animal model of severe sepsis and surgical injury
Cross et al. Use of monoclonal antibody combinations in the prevention of bacteremia caused by Escherichia coli 018: K1: H7
Uknis et al. Nosocomial infections and sepsis syndrome in critically ill surgical patients

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead